Tuesday, May 22, 2012
Technology Networks
Technology Networks
 |  |  |
|
|
 | Applied Molecular Diagnostics in Solid Tumours: Past, Present and Future Dr Brendan Pang, National University Health System, speaking at Molecular Diagnostics Asia 2011. |
 | Punctuated Evolution of Breast Tumors Revealed by Single Cell Sequencing Dr Nicholas Navin, MD Anderson Cancer Center, speaking at Single Cell Analysis Summit 2011. |
Personalized Medicine for Cancer
GlobalData
The report is an essential source of information on the Personalized Medicine for Cancer . The report also provides insights on the companion diagnostics and marketed personalized drugs for cancer.
MicroRNA Market Trends 2011
Select Biosciences Ltd
In this report, we focus upon the microRNA marketplace via primary market research that allows us to identify qualitative and quantitative trends from the bottom-up.
Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Report 2012
Select Biosciences Ltd
In this report, we focus upon the biology of CTCs and CSCs as well as explore the inter-relationship between these cell types based upon molecular events. Also presented are research trends which are for the isolation and study of CTCs, a potentially important tool for cancer diagnostics with special relevance to cancer metastatic mechanisms.
Circulating Tumor Cells (CTCs) Market Trends 2011
Select Biosciences Ltd
This is the latest and most up-to-date Market Report from Select Biosciences addressing the circulating tumor cells (CTCs) space. In this report, we focus upon the emerging marketplace for the isolation and study of CTCs, a potentially important tool for cancer diagnostics with special relevance to cancer metastasis and mechanisms thereof.
siRNA Screening Trends 2010
HTStec
This market report summarizes the results of HTStec’s industry-wide global web-based benchmarking survey on siRNA screening carried out in October 2010.
Single Cell Omics 2011
Select Biosciences Ltd
The single cell Omics revolution is the potential transformation of cellular heterogeneity from a source of noise to a source of new, as yet hidden discoveries.
Innovations in Combating Infectious Diseases: Opportunities in therapeutics and diagnostics through application of proteomics, genomics, nanotechnology, and novel sources of lead generation
Business Insights
This report makes a detailed and comprehensive analysis of the cutting edge of research aiming to reveal how bacteria, viruses, fungi, and prions infect and affect their hosts. It also assesses the new technologies and techniques that are being used to design and develop the anti-infective drugs and diagnostic methods of the 21st century.
Cancer Vaccines & Circulating Tumor Cells (CTCs) 2011 Report
Select Biosciences Ltd
This market report from Select Biosciences presents a comprehensive industry analysis of the cancer vaccines space as well as that of the emerging circulating tumor cells (CTCs) space. These two areas are evolving and expanding driven by the greater emphasis on personalized medicine especially in the cancer/oncology space.
Top 10 Drug Discovery Technologies - Strategic Analysis and Global Forecasts
MarketsandMarkets
The top 10 drug discovery technologies play a vital role in the growth of the entire pharmaceutical industry as they are the key contributors in the swift introduction of blockbusters and innovative drugs. The applications of these technologies in the introduction of drugs have created significant opportunities for market growth. The slow introduction of new blockbuster drugs is a major concern which the drug development companies are catering to by using these top technologies.
Polymerase Chain Reaction - A Global Market Outlook
Axis Research Mind
The report reviews the latest PCR market trends with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for life science sector investments. The study reveals profitable investment strategies for pharmaceutical manufacturers, biotechnology companies, laboratories, Contract Research Organizations (CROs) and many more in preferred locations.
GlobalData
The report is an essential source of information on the Personalized Medicine for Cancer . The report also provides insights on the companion diagnostics and marketed personalized drugs for cancer.
MicroRNA Market Trends 2011
Select Biosciences Ltd
In this report, we focus upon the microRNA marketplace via primary market research that allows us to identify qualitative and quantitative trends from the bottom-up.
Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Report 2012
Select Biosciences Ltd
In this report, we focus upon the biology of CTCs and CSCs as well as explore the inter-relationship between these cell types based upon molecular events. Also presented are research trends which are for the isolation and study of CTCs, a potentially important tool for cancer diagnostics with special relevance to cancer metastatic mechanisms.
Circulating Tumor Cells (CTCs) Market Trends 2011
Select Biosciences Ltd
This is the latest and most up-to-date Market Report from Select Biosciences addressing the circulating tumor cells (CTCs) space. In this report, we focus upon the emerging marketplace for the isolation and study of CTCs, a potentially important tool for cancer diagnostics with special relevance to cancer metastasis and mechanisms thereof.
siRNA Screening Trends 2010
HTStec
This market report summarizes the results of HTStec’s industry-wide global web-based benchmarking survey on siRNA screening carried out in October 2010.
Single Cell Omics 2011
Select Biosciences Ltd
The single cell Omics revolution is the potential transformation of cellular heterogeneity from a source of noise to a source of new, as yet hidden discoveries.
Innovations in Combating Infectious Diseases: Opportunities in therapeutics and diagnostics through application of proteomics, genomics, nanotechnology, and novel sources of lead generation
Business Insights
This report makes a detailed and comprehensive analysis of the cutting edge of research aiming to reveal how bacteria, viruses, fungi, and prions infect and affect their hosts. It also assesses the new technologies and techniques that are being used to design and develop the anti-infective drugs and diagnostic methods of the 21st century.
Cancer Vaccines & Circulating Tumor Cells (CTCs) 2011 Report
Select Biosciences Ltd
This market report from Select Biosciences presents a comprehensive industry analysis of the cancer vaccines space as well as that of the emerging circulating tumor cells (CTCs) space. These two areas are evolving and expanding driven by the greater emphasis on personalized medicine especially in the cancer/oncology space.
Top 10 Drug Discovery Technologies - Strategic Analysis and Global Forecasts
MarketsandMarkets
The top 10 drug discovery technologies play a vital role in the growth of the entire pharmaceutical industry as they are the key contributors in the swift introduction of blockbusters and innovative drugs. The applications of these technologies in the introduction of drugs have created significant opportunities for market growth. The slow introduction of new blockbuster drugs is a major concern which the drug development companies are catering to by using these top technologies.
Polymerase Chain Reaction - A Global Market Outlook
Axis Research Mind
The report reviews the latest PCR market trends with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for life science sector investments. The study reveals profitable investment strategies for pharmaceutical manufacturers, biotechnology companies, laboratories, Contract Research Organizations (CROs) and many more in preferred locations.
Good News for Nanomedicine
Quantum dots appear safe in pioneering study on primates.
NIH Study Finds that Coffee Drinkers have Lower Risk of Death
Older adults who drank coffee — caffeinated or decaffeinated — had a lower risk of death overall than others who did not drink coffee.
Finnish Researchers Discover Genes Inhibiting the Spread of Prostate Cancer
Researchers utilize the cell spot micro array technology to study the impacts of all genes in an entire genome in a single experiment.
Stabilizing Fanconi Anemia with Antioxidants
Fanconi anemia (FA) is a rare genetic disorder which affects one person in 350,000.
Genetic Predictor of Breast Cancer Response to Chemotherapy
Gene expression 'signatures' to measure the susceptibility of tumor cells to chemotherapy.
Revolutionary New Cancer Targeting Technology Described in Nature Medicine
Immunocore scientists manage to overcome cancer problem by boosting the ability of cancer-specific TCRs.
New Biomarkers Could Offer Vital Clues for Cancer Research
European funding for cancer research has led to some interesting results in recent years, says Carl-Johan Ivarsson, CEO at Qlucore.
Idera Pharmaceuticals Announces Top-line Results from Phase 2 Clinical Trial
IMO-2055 to be used in treatment of patients with advanced head and neck cancer.
Next-Generation “Epigenetic” Cancer Pill Shown to be Safe
Scientists have shown that a brand new type of cancer pill that exploits the emerging field of epigenetics is safe for human use, according to a Phase I trial reported today in Clinical Cancer Research.
Study Points to Potential New Treatment for Deadly Pancreatic Cancer
Cancer Research UK-funded scientists have shown how a promising new class of drugs might be used to treat aggressive forms of pancreatic cancer, according to a study published in Nature.
Quantum dots appear safe in pioneering study on primates.
NIH Study Finds that Coffee Drinkers have Lower Risk of Death
Older adults who drank coffee — caffeinated or decaffeinated — had a lower risk of death overall than others who did not drink coffee.
Finnish Researchers Discover Genes Inhibiting the Spread of Prostate Cancer
Researchers utilize the cell spot micro array technology to study the impacts of all genes in an entire genome in a single experiment.
Stabilizing Fanconi Anemia with Antioxidants
Fanconi anemia (FA) is a rare genetic disorder which affects one person in 350,000.
Genetic Predictor of Breast Cancer Response to Chemotherapy
Gene expression 'signatures' to measure the susceptibility of tumor cells to chemotherapy.
Revolutionary New Cancer Targeting Technology Described in Nature Medicine
Immunocore scientists manage to overcome cancer problem by boosting the ability of cancer-specific TCRs.
New Biomarkers Could Offer Vital Clues for Cancer Research
European funding for cancer research has led to some interesting results in recent years, says Carl-Johan Ivarsson, CEO at Qlucore.
Idera Pharmaceuticals Announces Top-line Results from Phase 2 Clinical Trial
IMO-2055 to be used in treatment of patients with advanced head and neck cancer.
Next-Generation “Epigenetic” Cancer Pill Shown to be Safe
Scientists have shown that a brand new type of cancer pill that exploits the emerging field of epigenetics is safe for human use, according to a Phase I trial reported today in Clinical Cancer Research.
Study Points to Potential New Treatment for Deadly Pancreatic Cancer
Cancer Research UK-funded scientists have shown how a promising new class of drugs might be used to treat aggressive forms of pancreatic cancer, according to a study published in Nature.
Debiopharm and Vifor Pharma Sign an Exclusive Agreement
Distribution and commercialization of Pamorelin® LA in Switzerland.
Agilent to Acquire Dako for $2.2 Billion
The largest acquisition in Agilent’s history is the next step in their growing role in clinical diagnostics.
Affymetrix and ScreenCell Announce Worldwide Distribution Agreement for CTC Technology
Combination of ScreenCell’s isolation devices and Affymetrix’ QuantiGene® ViewRNA ISH technology enables easy, accessible, sensitive, multiplex, low-cost system to enumerate and characterize CTCs and other rare cells.
Rosetta to Raise $2.2 Million in Registered Direct Offering
Company has entered into agreements with investors to purchase an aggregate of 632,057 ordinary shares at a price of $3.50 per share.
Affymetrix and ScreenCell Announce Worldwide Distribution Agreement
Affymetrix releases first circulating tumour cell platform technology for 4-color RNA-ISH.
Epizyme Announces Appoint Chief Medical Officer
Dr. Eric Hedrick has joins the personalized therapeutics company as Chief Medical Officer.
Partnership Provides Processing and Scale-up for AAV Vectors
Avalanche Biotechnologies, Inc. and Lonza announce global manufacturing collaborate for adeno-associated viral vectors for gene therapy.
Antisense Pharma Internationalizes Management Board
Dr. Philippe Calais appointed Chief Executive Officer.
Fluidigm Reports Financial Results for First Quarter 2012
Q1 total revenue up 26% compared to Q1 2011.
Agios Strengthens Team with Key Appointments and Promotion
The appointments include Robert J. DeVita, Ph.D., to the role of vice president of chemistry and Marion Dorsch, Ph.D., to the role of vice president of biology.
Distribution and commercialization of Pamorelin® LA in Switzerland.
Agilent to Acquire Dako for $2.2 Billion
The largest acquisition in Agilent’s history is the next step in their growing role in clinical diagnostics.
Affymetrix and ScreenCell Announce Worldwide Distribution Agreement for CTC Technology
Combination of ScreenCell’s isolation devices and Affymetrix’ QuantiGene® ViewRNA ISH technology enables easy, accessible, sensitive, multiplex, low-cost system to enumerate and characterize CTCs and other rare cells.
Rosetta to Raise $2.2 Million in Registered Direct Offering
Company has entered into agreements with investors to purchase an aggregate of 632,057 ordinary shares at a price of $3.50 per share.
Affymetrix and ScreenCell Announce Worldwide Distribution Agreement
Affymetrix releases first circulating tumour cell platform technology for 4-color RNA-ISH.
Epizyme Announces Appoint Chief Medical Officer
Dr. Eric Hedrick has joins the personalized therapeutics company as Chief Medical Officer.
Partnership Provides Processing and Scale-up for AAV Vectors
Avalanche Biotechnologies, Inc. and Lonza announce global manufacturing collaborate for adeno-associated viral vectors for gene therapy.
Antisense Pharma Internationalizes Management Board
Dr. Philippe Calais appointed Chief Executive Officer.
Fluidigm Reports Financial Results for First Quarter 2012
Q1 total revenue up 26% compared to Q1 2011.
Agios Strengthens Team with Key Appointments and Promotion
The appointments include Robert J. DeVita, Ph.D., to the role of vice president of chemistry and Marion Dorsch, Ph.D., to the role of vice president of biology.
 | ||||||||||||||||
|
Isolation of Urinary Exosomal miRNAs: Comparative Analysis of Different Methods
University of Verona
This study aims to identify and develop a robust and economical method for isolation of urinary exosomal miRNAs that can be routinely used for the analysis of miRNAs in different pathological conditions.
Cytotoxicity Screen of Mangiferin and its Major Metabolite Norathyriol in Human Tumor Cell Lines
DKFZ
Many natural products are available worldwide as potential chemoprotective agents against commonly occurring cancers, for example Mangiferin which has low bioavailability and is thought to be mainly available in the colon.
Automation of a Generic Fluorescence Methyltransferase Activity Assay
BioTek Instruments
Epigenetic processes are attracting considerable attention in drug discovery as their fundamental roles in controlling normal cell development and contributions to disease states become more clearly defined. This work combines a fluorescence-based assay with liquid handling and dispensing instrumentation and a multi-mode reader which can be used to monitor the biological activity of the histone methyltransferase (HMT) G9a, a model system.
UBS109, a novel curcumin analogue, promotes apoptosis in Head and Neck cancer cells through activating death receptor signaling pathway
Emory Chemical Biology Discovery Center
UBS109, a new curcumin analogue, exhibited a potent anticancer activity, inhibiting colony formation and cancer cell growth in vitro, and tumor growth in a xenograft animal model in vivo. 2. UBS109 rapidly blocks the NF-?B signaling pathway through the
miREC: A database of miRNAs involved in endometrial cancer
Life Sciences
The miREC database integrates public data about miRNAs and their target genes involved in the development of EAC in human, collected from recent literature. In future versions the database will be complemented with information derived by analyzing our in-house data and new published data by other researchers. The miREC database is the first database that focuses on integrating all available information about genes and miRNAs involved in endometrial cancer.
MicroRNA expression in normal and malignant prostate tissues
University of Skövde
In this study the aim was to identify a miRNA expression signature that could be used to separate between normal and malignant prostate tissues. Nine miRNAs were found to be differentially expressed and they could be used to separate between the normal and malignant tissues. A cross-validation procedure confirmed the generality of this expression signature, showing an accuracy of 85%.
Repurposing Drugs for the Treatment of Multi-Drug Resistant Breast Cance
National University of Ireland, Galway
In this study, the Johns Hopkins Clinical Compound Library, containing approximately 1,500 FDA and foreign-approved clinical compounds, was used to screen a multi-drug resistant, triple negative breast cancer cell line for drug sensitivity.
Intronic polymorphisms in Daucus carota AOX2b generate putative genotype specific miRNA
University of Évora
A study in the carrot alternative oxidase gene DcAOX2b from several individual plant genotypes of D. carota cv. Rotin revealed the frequent occurrence of intron length polymorphisms (ILPs). Here we will present an in silico analysis performed in order to identify putative miRNA sites at three different sizes of intron 1. The overall research approach aims to develop functional marker candidates for carrot plant breeding.
A high-throughput colony formation assay for profiling novel compounds and RNAi reagents using the Acumen® eX3
TTP Labtech Ltd
Cell colony formation assays measure a cell's ability to grow unattached to a surface and have applications in a range of areas including hematopoietic stem cell research, cell transformation studies and the prediction of responses of tumors to chemotherapeutic agents. The results of this study demonstrated that Acumen eX3 can be used as a high-throughput platform for investigation of effects of test compounds and RNAi reagents on cell colony formation.
Altering microRNA miR-15a/16 Levels as Potential Therapy in CLL: Extrapolating from the de novo NZB Mouse Model
University of Medicine and Dentistry of New Jersey
Expression of miR15a/16-1 was increased using lentiviral delivery (in vitro and in vivo) or by BSAP knockdown to inhibit B-CLL malignancy.
University of Verona
This study aims to identify and develop a robust and economical method for isolation of urinary exosomal miRNAs that can be routinely used for the analysis of miRNAs in different pathological conditions.
Cytotoxicity Screen of Mangiferin and its Major Metabolite Norathyriol in Human Tumor Cell Lines
DKFZ
Many natural products are available worldwide as potential chemoprotective agents against commonly occurring cancers, for example Mangiferin which has low bioavailability and is thought to be mainly available in the colon.
Automation of a Generic Fluorescence Methyltransferase Activity Assay
BioTek Instruments
Epigenetic processes are attracting considerable attention in drug discovery as their fundamental roles in controlling normal cell development and contributions to disease states become more clearly defined. This work combines a fluorescence-based assay with liquid handling and dispensing instrumentation and a multi-mode reader which can be used to monitor the biological activity of the histone methyltransferase (HMT) G9a, a model system.
UBS109, a novel curcumin analogue, promotes apoptosis in Head and Neck cancer cells through activating death receptor signaling pathway
Emory Chemical Biology Discovery Center
UBS109, a new curcumin analogue, exhibited a potent anticancer activity, inhibiting colony formation and cancer cell growth in vitro, and tumor growth in a xenograft animal model in vivo. 2. UBS109 rapidly blocks the NF-?B signaling pathway through the
miREC: A database of miRNAs involved in endometrial cancer
Life Sciences
The miREC database integrates public data about miRNAs and their target genes involved in the development of EAC in human, collected from recent literature. In future versions the database will be complemented with information derived by analyzing our in-house data and new published data by other researchers. The miREC database is the first database that focuses on integrating all available information about genes and miRNAs involved in endometrial cancer.
MicroRNA expression in normal and malignant prostate tissues
University of Skövde
In this study the aim was to identify a miRNA expression signature that could be used to separate between normal and malignant prostate tissues. Nine miRNAs were found to be differentially expressed and they could be used to separate between the normal and malignant tissues. A cross-validation procedure confirmed the generality of this expression signature, showing an accuracy of 85%.
Repurposing Drugs for the Treatment of Multi-Drug Resistant Breast Cance
National University of Ireland, Galway
In this study, the Johns Hopkins Clinical Compound Library, containing approximately 1,500 FDA and foreign-approved clinical compounds, was used to screen a multi-drug resistant, triple negative breast cancer cell line for drug sensitivity.
Intronic polymorphisms in Daucus carota AOX2b generate putative genotype specific miRNA
University of Évora
A study in the carrot alternative oxidase gene DcAOX2b from several individual plant genotypes of D. carota cv. Rotin revealed the frequent occurrence of intron length polymorphisms (ILPs). Here we will present an in silico analysis performed in order to identify putative miRNA sites at three different sizes of intron 1. The overall research approach aims to develop functional marker candidates for carrot plant breeding.
A high-throughput colony formation assay for profiling novel compounds and RNAi reagents using the Acumen® eX3
TTP Labtech Ltd
Cell colony formation assays measure a cell's ability to grow unattached to a surface and have applications in a range of areas including hematopoietic stem cell research, cell transformation studies and the prediction of responses of tumors to chemotherapeutic agents. The results of this study demonstrated that Acumen eX3 can be used as a high-throughput platform for investigation of effects of test compounds and RNAi reagents on cell colony formation.
Altering microRNA miR-15a/16 Levels as Potential Therapy in CLL: Extrapolating from the de novo NZB Mouse Model
University of Medicine and Dentistry of New Jersey
Expression of miR15a/16-1 was increased using lentiviral delivery (in vitro and in vivo) or by BSAP knockdown to inhibit B-CLL malignancy.
Dual-Glo Luciferase Reporter-Gene Assay on the SpectraMax M5, LMax II384 and Analyst GT Microplate Readers
Molecular Devices
Reporter-gene assays are used to study eukaryotic gene expression. Dual genetic reporters are commonly used in transient transfections of cultured cells to minimize experimental variability. Recently, Promega introduced a Dual-Glo Lucoferase assay system which replaced the outdated ‘flash’ assays used previously. Ensuring both genetic reporters have different substrate requirements enables them to be detected using a single reaction mixture.
Sequence-Specific DNA Assay
Molecular Devices
The Threshold® system from Molecular Devices, together with the Immuno Ligand Assay (ILA) kit can be used to measure specific DNA sequences. Biotinylated or fluorescienated oligonucleotide probes, specific to the target sequence, anneal to the digested target DNA creating a probe-target hybrid which can then be detected and quantified against a standard curve, with pleasing results.
Measurement of Proteasome Inhibition in Live Cells in Molecular Devices Microplate Fluorometers
Molecular Devices
The proteasome is a massive protein complex which can recognize and bind targeted proteins, and inject them into the central core where the proteins are successively degraded into short peptides. Whereas protein synthesis is well-understood after decades of study, major advances in our knowledge of protein degradation have occurred only in the last two decades.
A Fast and Simple Method For Measuring P-Glycoprotein (Pgp) Inhibition
BMG Labtech
Pgp expression has been linked to the effl ux of chemotherapeutic drugs in human cancers leading to multidrug resistance. Pgp activity can also result in low oral absorption and poor brain penetration. Interaction of drugs with the Pgp may also cause an increase in toxicity of co-administered compounds.
Validated Luminometric DLR™ Reporter Gene Assay with Thermo Scientific Varioskan® Flash
Thermo Fisher Scientific
One of the most common luminometric assays is Dual Luciferase® Reporter Assay from Promega corp. This application note shows how this assay is performed with Varioskan Flash multitechnology microplate reader. The note includes the performance of the normal DLR assay and results from some tests showing important aspects of the basic behaviour and performance of the DLR™ chemistry. This paper describes the overall efficiency of the Varioskan Flash in the measurement of DLR assay.
FabRICATOR® - perfect F(ab?)2 fragments in minutes
Genovis
Fab and F(ab?)2 antibody fragments are used in applications or assays where the presence of the Fc region may cause problems. If antibodies are used for staining of a specific target in tissues like spleen, lymph or in peripheral blood preparations, cells with Fc receptors (macrophages, monocytes, natural killer cells and B lymphocytes) can bind to the Fc region of the antibody and cause a background staining in areas that do not contain any antigen. Fab and F(ab?)2 fragments are also desirable
DNA Transfection with High Transfection Efficiency and Low Toxicity Using NIMT®FeOfection
Genovis
Transfection of DNA is used to analyze and study functions of genes, regulatory sequences and metabolism in living cells. To study cells and the effects of the gene transfer researchers need methods that give high transfection efficiencies, during a period of time and with low toxicity. Lipid based transfection agents often generates good transfection rates but with high toxicity. Here the novel NIMT®FeOfection transfection agents are tested for its ability to transfect different cell types and
Efficient Delivery of siRNA in Human Renal Cell Carcinoma Cell Line Using NIMT®FeOfection | PURPLE
Genovis
Short interfering RNA (siRNA) transfection is an exciting new method for introducing foreign genetic information by inducing RNA interference. siRNA works by silencing key sequences on messenger RNA, which turns off specific genes by cleaving them on the RNA strand. For this process to work efficiently one of the key steps is delivery of the siRNA into cells. Here, novel siRNA delivery agent NIMT®FeOfection|PURPLE is tested for its ability to deliver siRNA.
Knockdown of BACE-1, an Alzheimer’s Disease Drug Target, with NIMT®FeOfection|PURPLE
Genovis
Small interfering RNA (siRNA) has become a widely used tool over the past years in the study of gene function and shows potential for drug development. However, in vivo siRNA delivery is the major obstacle that has to be overcome. The commercial cationic lipid based transfection reagents are toxic to the cells and are not compatible for in vivo application.
NIMT®FeOfection|PURPLE in siRNA Delivery into HEK293 Cells
Genovis
Short interfering RNA (siRNA) is used in many different applications to study gene silencing. For successful gene silencing the siRNA delivery method is crucial. An attentive delivery agent should stabilize the siRNA and give minimal background effects on cell viability and metabolism. NIMT®FeOfection|PURPLE is explored here for its siRNA delivery ability.
Molecular Devices
Reporter-gene assays are used to study eukaryotic gene expression. Dual genetic reporters are commonly used in transient transfections of cultured cells to minimize experimental variability. Recently, Promega introduced a Dual-Glo Lucoferase assay system which replaced the outdated ‘flash’ assays used previously. Ensuring both genetic reporters have different substrate requirements enables them to be detected using a single reaction mixture.
Sequence-Specific DNA Assay
Molecular Devices
The Threshold® system from Molecular Devices, together with the Immuno Ligand Assay (ILA) kit can be used to measure specific DNA sequences. Biotinylated or fluorescienated oligonucleotide probes, specific to the target sequence, anneal to the digested target DNA creating a probe-target hybrid which can then be detected and quantified against a standard curve, with pleasing results.
Measurement of Proteasome Inhibition in Live Cells in Molecular Devices Microplate Fluorometers
Molecular Devices
The proteasome is a massive protein complex which can recognize and bind targeted proteins, and inject them into the central core where the proteins are successively degraded into short peptides. Whereas protein synthesis is well-understood after decades of study, major advances in our knowledge of protein degradation have occurred only in the last two decades.
A Fast and Simple Method For Measuring P-Glycoprotein (Pgp) Inhibition
BMG Labtech
Pgp expression has been linked to the effl ux of chemotherapeutic drugs in human cancers leading to multidrug resistance. Pgp activity can also result in low oral absorption and poor brain penetration. Interaction of drugs with the Pgp may also cause an increase in toxicity of co-administered compounds.
Validated Luminometric DLR™ Reporter Gene Assay with Thermo Scientific Varioskan® Flash
Thermo Fisher Scientific
One of the most common luminometric assays is Dual Luciferase® Reporter Assay from Promega corp. This application note shows how this assay is performed with Varioskan Flash multitechnology microplate reader. The note includes the performance of the normal DLR assay and results from some tests showing important aspects of the basic behaviour and performance of the DLR™ chemistry. This paper describes the overall efficiency of the Varioskan Flash in the measurement of DLR assay.
FabRICATOR® - perfect F(ab?)2 fragments in minutes
Genovis
Fab and F(ab?)2 antibody fragments are used in applications or assays where the presence of the Fc region may cause problems. If antibodies are used for staining of a specific target in tissues like spleen, lymph or in peripheral blood preparations, cells with Fc receptors (macrophages, monocytes, natural killer cells and B lymphocytes) can bind to the Fc region of the antibody and cause a background staining in areas that do not contain any antigen. Fab and F(ab?)2 fragments are also desirable
DNA Transfection with High Transfection Efficiency and Low Toxicity Using NIMT®FeOfection
Genovis
Transfection of DNA is used to analyze and study functions of genes, regulatory sequences and metabolism in living cells. To study cells and the effects of the gene transfer researchers need methods that give high transfection efficiencies, during a period of time and with low toxicity. Lipid based transfection agents often generates good transfection rates but with high toxicity. Here the novel NIMT®FeOfection transfection agents are tested for its ability to transfect different cell types and
Efficient Delivery of siRNA in Human Renal Cell Carcinoma Cell Line Using NIMT®FeOfection | PURPLE
Genovis
Short interfering RNA (siRNA) transfection is an exciting new method for introducing foreign genetic information by inducing RNA interference. siRNA works by silencing key sequences on messenger RNA, which turns off specific genes by cleaving them on the RNA strand. For this process to work efficiently one of the key steps is delivery of the siRNA into cells. Here, novel siRNA delivery agent NIMT®FeOfection|PURPLE is tested for its ability to deliver siRNA.
Knockdown of BACE-1, an Alzheimer’s Disease Drug Target, with NIMT®FeOfection|PURPLE
Genovis
Small interfering RNA (siRNA) has become a widely used tool over the past years in the study of gene function and shows potential for drug development. However, in vivo siRNA delivery is the major obstacle that has to be overcome. The commercial cationic lipid based transfection reagents are toxic to the cells and are not compatible for in vivo application.
NIMT®FeOfection|PURPLE in siRNA Delivery into HEK293 Cells
Genovis
Short interfering RNA (siRNA) is used in many different applications to study gene silencing. For successful gene silencing the siRNA delivery method is crucial. An attentive delivery agent should stabilize the siRNA and give minimal background effects on cell viability and metabolism. NIMT®FeOfection|PURPLE is explored here for its siRNA delivery ability.
©2012 Technology Networks, all rights reserved.